Please assess the completion status of the following clinical trial:

Trial Title: Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 14.0

Eligibility Criteria:
Subject Inclusion Criteria~All participants~* Be a healthy male, or healthy female participant (excluding diabetes mellitus in Part 3 participants) of non-child bearing potential. A female non-child bearing potential is one who is postmenopausal without menses for at least 1 year or whose status is post hysterectomy, bilateral oophorectomy, or tubal ligation.~* Be judged to be in good health based on medical history, physical exam, vital sign measurements, electrocardiogram (ECG) and laboratory safety tests~* Have adequate venous access to support execution of trial procedures~For Parts 1 and 2 (Healthy adult participants)~* Healthy male and female participants between the ages of 18 and 50 years (inclusive)~* Have a Body Mass Index (BMI) ≥18.5 kg/m\^2 and ≤28.0 kg/m\^2 at screening~* Have fasting blood glucose values at screening must be \<100 mg/dL~* Be a non-smoker and/or has not used nicotine or nicotine-containing products (e.g., nicotine patch) for at least approximately 3 months.~For Part 3 (Adult participants with T1DM):~* Be male, or female of non-childbearing potential between 18 to 60 years of age~* Have a diagnosis of T1DM as defined by standard diagnostic criteria for ≥12 months at time of the pretrial (screening) visit~* Have a BMI ≥18.5 kg/m\^2 and ≤32 kg/m\^2 at screening.~* Be on stable doses of basal insulin over the 2-week period prior to screening and over the 2 weeks prior to dosing~* Have a total daily insulin requirement (basal plus prandial) of ≤1.2 units/kg at screening~* Have a hemoglobin A1C (HbA1c) ≤10% at the screening visit.~* Be a non-smoker or smoker who uses no more than 5 cigarettes or equivalent (e.g., e-cigarettes) per day over the prior 3-month period also may be enrolled (at the discretion of the investigator).~* Have a serum C-peptide concentration ≤0.7 ng/mL with a concurrent plasma glucose \>90 mg/dL at screening or anytime within 24 weeks prior to screening.~For Part 4 (Adult participants with T2DM):~* Diagnosis of T2DM as defined by standard diagnostic criteria for ≥12 months at time of pretrial screening.~* Have a BMI ≥18.5 kg/m2 and ≤35.0 kg/m\^2 at screening. BMI = mass (kg)/height (m)\^2.~* Have a hemoglobin A1C (HbA1c) ≥6.5% and ≤10.0%.~* T2DM participants are not required to have been on insulin. If using insulin as background therapy, subjects should have a total daily insulin requirement of ≤1.2 units/kg, and have been on stable doses of basal insulin over the 2-week period prior to screening and over the 2 weeks prior to dosing.~* Be a non-smoker or smoker who uses no greater than 5 cigarettes or equivalent (e.g., e-cigarettes) daily over the prior 3-month period.~Subject Exclusion Criteria~All participants~* Is mentally or legally incapacitated~* Has a history of clinically significant endocrine (excluding diabetes mellitus in Part 3 participants), gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic seizures) abnormalities or diseases.~* Has a systolic blood pressure (SBP) ≥140 mm Hg and/or a diastolic blood pressure (DBP) ≥90 mm Hg at screening.~* Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV) at screening.~* Has a history of cancer (malignancy) Exceptions: (1) Participants with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) Participants with other malignancies which have been successfully treated ≥10 years prior to the pretrial (screening) visit~* Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e. systemic allergic reaction) to prescription or non-prescription drugs or food.~* Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit.~* Has participated in another investigational trial within 4 weeks.~* Has been randomized to, and received MK-5160 in prior clinical studies.~* Has a QTcF interval \>450 msec, has a history of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of Long QT Syndrome).~* Has uncorrected hypokalemia~* Has uncorrected hypomagnesemia~* Is taking concomitant medications that prolong the QT/QTc interval.~* Is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies beginning approximately 2 weeks prior to administration of the initial dose of trial drug, throughout the trial, until the post-trial visit.~* Has had a vaccination within 12 weeks of the pretrial visit.~* Consumes greater than 3 glasses of alcoholic beverages per day.~* Consumes excessive amounts, defined as greater than 6 servings caffeinated beverages per day.~* Is currently a regular or recreational user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 6 months~* Has used systemic (intravenous, oral, inhaled) glucocorticoids within 3 months of screening or is anticipated to require treatment with systemic glucocorticoids during study participation.~For Part 1 and Part 2 (Healthy Adult Participants)~- Has an estimated creatinine clearance of \<90 mL/min based on Cockcroft-Gault equation~For Part 3 (Adult participants with T1DM):~* Has a history of diabetic ketoacidosis in the last 6 months prior to screening.~* Has an estimated creatinine clearance of \<60 mL/min based on the Cockcroft-Gault equation at screening~* Has the diagnosis of hypoglycemia unawareness, or has had one or more severe hypoglycemic episodes associated with hypoglycemic seizures, comas or unconsciousness within 6 months prior to dosing.~* Has other major medical problems requiring medication (i.e., history of myocardial infarction (MI), hypercholesterolemia).~* Has a known history of celiac disease or significant food allergy, at the discretion of the investigator and Sponsor.~* Has a history of hypersensitivity to pharmacologic insulins or to any of the inactive ingredients in recombinant human insulin, or to any E.coli-derived drug product.~For Part 4 (Adult participants with T2DM):~* Participant has an estimated creatinine clearance of \<60 mL/min based on the Cockcroft-Gault equation.~* Has a history of diabetic ketoacidosis in the last 6 months prior to screening.~* Has the diagnosis of hypoglycemia unawareness, or has had one or more severe hypoglycemic episodes associated with hypoglycemic seizures, comas or unconsciousness within 6 months prior to dosing.~* Has a known history of celiac disease or significant food allergy, at the discretion of the Investigator and Sponsor.~* Has been treated with a thiazolidinedione or injectable non-insulin anti-diabetic therapy within the past three months prior to dosing.~* Has a history of hypersensitivity to pharmacologic insulins or to any of the inactive ingredients in regular human insulin, or to any E.coli-derived drug product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Part 1, MK-1092, 4.0 nmol/kg (Type: EXPERIMENTAL): MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
- Part 1, MK-1092, 8.0 nmol/kg (Type: EXPERIMENTAL): MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
- Part 1, MK-1092, 16 nmol/kg (Type: EXPERIMENTAL): MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
- Part 1, MK-1092, 32 nmol/kg (Type: EXPERIMENTAL): MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
- Part 1, MK-1092, 64 nmol/kg (Type: EXPERIMENTAL): MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
- Part 1, Glargine, 3.0 nmol/kg (Type: ACTIVE_COMPARATOR): Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
- Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg (Type: EXPERIMENTAL): MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
- Part 3, MK-1092, 8.0 nmol/kg (Type: EXPERIMENTAL): MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
- Part 3, MK-1092, 32 nmol/kg (Type: EXPERIMENTAL): MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
- Part 3, Glargine, 3.0 nmol/kg (Type: ACTIVE_COMPARATOR): Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
- Part 4, MK-1092, 32 nmol/kg (Type: EXPERIMENTAL): MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
- Part 4, MK-1092, 16 nmol/kg (Type: EXPERIMENTAL): MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
- Part 4, MK-1092, 64 nmol/kg (Type: EXPERIMENTAL): MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
- Part 4, Glargine, 3.0 nmol/kg (Type: ACTIVE_COMPARATOR): Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete